New asthma inhaler shows promise in early trial
NCT ID NCT07326995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new corticosteroid inhaler called PA9159 in 60 adults with asthma. Participants receive one of three doses or a placebo for 28 days. The main goal is to see if the drug improves lung function, measured by how much air they can exhale in one second. The trial is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PA9159 (a new corticosteroid) given as an inhaler
- What this could lead to
- If successful, this could provide a new treatment option for controlling asthma symptoms.
- What could go wrong
- This is an early Phase 2 trial with only 60 people, so results may not apply to everyone. The drug may not work better than existing treatments or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIAL ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could vitamin d levels influence asthma control?
- Could a chromium supplement help obese adults breathe easier?
- Can acupuncture stop an asthma attack? new study investigates
- Golfers test N95 masks to breathe easy in wildfire smoke
- Massive study reveals hidden dangers of common steroid treatments
- Breath prints may reveal lung disease secrets without needles